ID: ALA440542

Max Phase: Preclinical

Molecular Formula: C9H15F3OS

Molecular Weight: 228.28

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCSCC(=O)C(F)(F)F

Standard InChI:  InChI=1S/C9H15F3OS/c1-2-3-4-5-6-14-7-8(13)9(10,11)12/h2-7H2,1H3

Standard InChI Key:  JKYLDTTWQQEIHX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 228.28

Molecular Weight (Monoisotopic): 228.0796

AlogP: 3.43

#Rotatable Bonds: 7

Polar Surface Area: 17.07

Molecular Species: NEUTRAL

HBA: 2

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 1

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.86

CX Basic pKa:

CX LogP: 3.96

CX LogD: 3.96

Aromatic Rings: 0

Heavy Atoms: 14

QED Weighted: 0.62

Np Likeness Score: -0.68

References

1. Wheelock CE, Colvin ME, Uemura I, Olmstead MM, Sanborn JR, Nakagawa Y, Jones AD, Hammock BD..  (2002)  Use of ab initio calculations to predict the biological potency of carboxylesterase inhibitors.,  45  (25): [PMID:12459025] [10.1021/jm020072w]

2. Wheelock CE, Nishi K, Ying A, Jones PD, Colvin ME, Olmstead MM, Hammock BD..  (2008)  Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH).,  16  (4): [PMID:18023188] [10.1016/j.bmc.2007.10.081]

3. Harada T, Nakagawa Y, Wadkins RM, Potter PM, Wheelock CE..  (2009)  Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis.,  17  (1): [PMID:19062296] [10.1016/j.bmc.2008.11.008]

4. Wheelock CE, Severson TF, Hammock BD..  (2001)  Synthesis of new carboxylesterase inhibitors and evaluation of potency and water solubility.,  14  (12): [PMID:11743738] [10.1021/tx015508+]

5. Wheelock CE, Nakagawa Y, Akamatsu M, Hammock BD..  (2003)  Use of classical and 3-D QSAR to examine the hydration state of juvenile hormone esterase inhibitors.,  11  (23): [PMID:14604674] [10.1016/j.bmc.2003.08.023]

6. Mouchlis VD, Morisseau C, Hammock BD, Li S, McCammon JA, Dennis EA..  (2016)  Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A₂.,  24  (20): [PMID:27320659] [10.1016/j.bmc.2016.05.009]

Source

Source(1):

• Scientific Literature